Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.

Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators.; ROCKET AF Steering Committee Investigators..

J Am Heart Assoc. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197.

2.

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators..

Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.

3.

Role of thrombolysis in reperfusion therapy for management of AMI: Indian scenario.

Dalal J, Sahoo PK, Singh RK, Dhall A, Kapoor R, Krishnamurthy A, Shetty SR, Trivedi S, Kahali D, Shah B, Chockalingam K, Abdullakutty J, Shetty PK, Chopra A, Ray R, Desai D, Pachiyappan, Ratnaparkhi G, Sharma M, Sambasivam KA.

Indian Heart J. 2013 Sep-Oct;65(5):566-85. doi: 10.1016/j.ihj.2013.08.032. Epub 2013 Sep 23. Review. No abstract available.

4.

Prevalence of tobacco use in urban, semi urban and rural areas in and around Chennai City, India.

Chockalingam K, Vedhachalam C, Rangasamy S, Sekar G, Adinarayanan S, Swaminathan S, Menon PA.

PLoS One. 2013 Oct 1;8(10):e76005. doi: 10.1371/journal.pone.0076005. eCollection 2013.

5.

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Maggioni AP, Greene SJ, Fonarow GC, Böhm M, Zannad F, Solomon SD, Lewis EF, Baschiera F, Hua TA, Gimpelewicz CR, Lesogor A, Gheorghiade M; ASTRONAUT Investigators and Coordinators..

Eur Heart J. 2013 Oct;34(40):3117-27. doi: 10.1093/eurheartj/eht342. Epub 2013 Sep 2.

6.

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators..

JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. Erratum in: JAMA. 2013 Apr 10;309(14):1461.

PMID:
23478743
7.

Treatment of anemia with darbepoetin alfa in systolic heart failure.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees.; RED-HF Investigators..

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.

8.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).

McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators..

Eur J Heart Fail. 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17.

9.

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.

Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators..

Lancet Neurol. 2012 Apr;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X. Epub 2012 Mar 7.

PMID:
22402056
10.

PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.

Chamoun AM, Chockalingam K, Bobardt M, Simeon R, Chang J, Gallay P, Chen Z.

Antimicrob Agents Chemother. 2012 Feb;56(2):672-81. doi: 10.1128/AAC.05722-11. Epub 2011 Nov 14.

11.

Rivaroxaban in patients with a recent acute coronary syndrome.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators..

N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.

12.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators..

N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.

13.

Malignant syphilis with human immunodeficiency virus infection.

Rajan J, Prasad PV, Chockalingam K, Kaviarasan PK.

Indian Dermatol Online J. 2011 Jan;2(1):19-22. doi: 10.4103/2229-5178.79864.

14.

Eplerenone in patients with systolic heart failure and mild symptoms.

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group..

N Engl J Med. 2011 Jan 6;364(1):11-21. doi: 10.1056/NEJMoa1009492. Epub 2010 Nov 14.

15.

Creation and characterization of a cell-death reporter cell line for hepatitis C virus infection.

Chen Z, Simeon RL, Chockalingam K, Rice CM.

Antiviral Res. 2010 May;86(2):220-3. doi: 10.1016/j.antiviral.2010.02.321. Epub 2010 Feb 25.

16.

A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.

Chockalingam K, Simeon RL, Rice CM, Chen Z.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3764-9. doi: 10.1073/pnas.0915117107. Epub 2010 Feb 8.

17.

Elephantiasis of the external genitalia: a sequel to cutaneous tuberculosis.

Padmavathy L, Rao LL, Chockalingam K, Ethirajan N, Dhanlakshmi M.

Indian J Dermatol. 2009;54(1):52-5. doi: 10.4103/0019-5154.48988.

18.

Directed evolution of orthogonal ligand specificity in a single scaffold.

McLachlan MJ, Chockalingam K, Lai KC, Zhao H.

Angew Chem Int Ed Engl. 2009;48(42):7783-6. doi: 10.1002/anie.200903413. No abstract available.

PMID:
19746501
19.

Development of a bacteriophage-based system for the selection of structured peptides.

Chockalingam K, Lu HD, Banta S.

Anal Biochem. 2009 May 1;388(1):122-7. doi: 10.1016/j.ab.2009.01.042. Epub 2009 Feb 5.

PMID:
19454225
20.

Design and application of stimulus-responsive peptide systems.

Chockalingam K, Blenner M, Banta S.

Protein Eng Des Sel. 2007 Apr;20(4):155-61. Epub 2007 Mar 21. Review.

PMID:
17376876

Supplemental Content

Loading ...
Support Center